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INVESTIGATING THE ROLE OF AUTISM GENE UBE3A IN 
THE REGULATION OF NEURONAL PROTEINS 
EMMANUEL MAGSINO 
ABSTRACT 
 
UBE3A is a protein with dual functions as an E3 ubiquitin ligase and as a Steroid 
Hormone Receptor (SHR) transcriptional coactivator. It is expressed ubiquitously in 
tissues and has significant importance in neurons, where it is expressed exclusively from 
the maternal allele. Thus, while UBE3A has a wide variety of targets in various tissues, it 
is especially important in the brain as UBE3A regulates several aspects of neuronal 
growth, function, and maintenance. Therefore deficits of Ube3a cause Angelman 
Syndrome (AS) and increased dosage causes Autism Spectrum Disorder (ASD), two 
neurological disorders. The pathological phenotype of both diseases involves behavioral 
dysfunctions in learning, motor skills, and sociability. Through microarray studies, our 
laboratory has found that Ube3a is involved in the regulation of neuronal proteins such as 
CBLN1, which has been found to have significant importance in parallel fiber synapse 
formation onto Purkinje cells. To determine how regulation of CBLN1 occurs, mutant 
variants of human Ube3a isoform III were then generated. E3 ligase-dead, substrate-
binding defective, nonphosphorylatable mutant, and phosphor-mimetic mutants were 
produced and inserted into a pLVX-IRES-mCherry vector.  
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A quantitative transcriptional analysis demonstrated that increasing wild-type 
(WT) UBE3A decreased Cbln1 expression. The ligase dead mutant mimicked the WT 
suggesting that E3 ligase activity is not required in the regulation of Cbln1. The 
nonphosphorylatable mutant demonstrated an increase in Cbln1 expression, which may 
be due to a dominant negative effect on native UBE3A causing its degradation. The 
phosphor-mimetic mutant had no statistical effect. This may be due to its inability to 
enter the nucleus and affect transcription. The substrate-binding mutant also showed no 
statistical effect possibly because of its inability to bind to any substrate and that may be 
necessary to regulate transcription. These preliminary results demonstrate that UBE3A 
may be regulating CBLN1 at the transcriptional level independent of its E3 ubiquitin 
ligase function. Future studies will be required to more precisely determine the 
mechanisms involved in UBE3A’s regulation of CBLN1. 
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1 INTRODUCTION  
 
UBE3A is a protein first discovered for interacting with the E6 protein of the 
Human Papilloma Virus (HPV). Formerly known as E6 Associated Protein (E6AP), 
Ube3a is expressed throughout various tissues in the body and is especially significant in 
the brain, where expression is imprinted via the maternal allele. It has dual functions as 
an E3 Ubiquitin Ligase and as a Steroid Hormone Receptor Transcriptional Coactivator. 
Thus, it has a wide variety of targets which allows it to regulate many cellular functions. 
This is especially important in neurology as Ube3a regulates several aspects of neuronal 
function including growth and maintenance. As such, impairment of UBE3A via loss of 
function, loss of expression, or overexpression causes diseases including Angelman 
Syndrome (AS) and Autism Spectrum Disorder (ASD). 
 
1.1 Discovery of UBE3A: An Associated Protein of HPV Protein E6 
 UBE3A was first discovered by Huibregtse et al., in 1991. During this time the 
100-kDa protein was named E6 Associated Protein (E6AP), because it was found to 
interact with the E6 protein of the Human Papilloma Virus (HPV). Further 
experimentation from Huibregtse et al., (1993) led to the discovery that the E6/E6AP 
complex binds to the cell-cycle protein p53, which is involved in oncogenesis, and causes 
its degradation via the ubiquitin-proteasome pathway. Continued research on the 
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molecular mechanism of p53’s ubiquitin degradation and on E6AP by itself revealed 
E6AP’s primary function as an E3 ubiquitin ligase, which has the ability to operate 
independently of the E6 protein (Scheffner et al., 1993, Ciechanover et al., 1994, Shkedy 
et al., 1994). 
 
1.2 UBE3A Has Three Different Isoforms 
 
 
Figure 1. The Isoforms of UBE3A Isoform II has 23 additional amino acid residues while Isoform III has 20 
additional amino acids. Isoforms I and III locate to the nucleus while Isoform II locates to the cytoplasm. A nuclear 
localization sequence may be in Isoform I which is overridden by the additional sequence in Isoform II. Appended 
from Condon (2009). 
E6AP is encoded in the Ube3a gene, which is found on the human chromosomal 
locus 15q11-q13 and is the gene that the protein derives its current name (El Hokayem & 
Nawaz, 2014). The mRNA sequence of Ube3a is approximately 5-kb and is coded by a 
coding region of 60 kb/10 exons. Upstream exons (U1-U2-U3-U4) are alternatively 
spliced, generating mRNA variants which in turn form three different isoforms of 
UBE3A as shown in Figure 1. Isoform II has an extra 23 AA at the N-terminus compared 
to isoform I, while isoform III has an additional 20 AA at the N-terminus (El Hokayem & 
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Nawaz, 2014). There is currently no known function for the additional amino acids. 
However, Condon (2009) hypothesizes that these amino acids may be involved in the 
cellular localization of Ube3a. 
 
1.3 Localization of UBE3A 
Condon (2009) researched the cellular localization of each UBE3A isoform. By 
tagging each isoform with a pEYFP C-terminal tag within Clone 9 cells and primary 
hippocampal neurons, Condon was able to determine the cellular localization of the three 
isoforms. Within Clone 9 cells, Isoform I and Isoform III were found to concentrate in 
the nucleus while Isoform II was found exclusively in the cytoplasm. Within primary 
hippocampal neurons UBE3A was found in the soma, axons, dendrites, as well as both 
pre- and post-synaptic compartments. In this study, UBE3A was not found to localize 
within any specific compartment in the nucleus or cytoplasm. Condon suggests that these 
results may indicate that although UBE3A does not contain a classical nuclear 
localization sequence, the signal for nuclear localization must be in isoform I and that the 
additional amino acids in isoform II override the signal.  Further analysis from this study 
revealed that UBE3A has the ability to associate with light and medium membrane 
compartments such as vesicles, endosomes, and Golgi membranes but does not associate 
with endoplasmic reticulum. 
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Yi et al. (2015) also found that PKA phosphorylates the mouse homologue of 
UBE3A at the T485 residue. This phosphorylation of UBE3A was found to control the 
localization of the Ube3a isoform studied by Yi et al. As shown in Figure 2, the 
phosphorylated form was only found in the cytoplasm. On the other hand, 
nonphosphorylated UBE3A was found primarily in the nucleus. This phosphorylation 
control may explain why classical nuclear localization sequences are not found in 
UBE3A. 
 
Figure 2. Localization of UBE3A Affected By Phosphorylation The phosphorylation of UBE3A at the T485 residue 
was found to control its localization. Upon phosphorylation (pT485), UBE3A was found to localize within the 
cytoplasm and was not found in the nucleus. When UBE3A was not phosphorylated it was found primarily in the 
nucleus. Figure appended from Yi et al (2015).  
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1.4 Expression Pattern: Ube3a Is Imprinted In Neurons 
Throughout the peripheral tissues Ube3a is expressed via both parental alleles. In 
contrast, Ube3a is an imprinted gene in neurons, expressed only through the maternal 
allele. Albrecht et al. (1997) found that in the brains of developing wild-type mice, Ube3a 
transcripts were initially detected by embryonic age, E8.5. Ube3a was expressed broadly 
throughout the brain neuro-epithelium by E10.5 and as development continued the 
expression of Ube3a became more localized. By E15.5 a high level of Ube3a mRNA was 
detected in the cerebral cortex, cerebellar neuro-epithelium, hippocampus, basal ganglia, 
thalamus, tectum, tegmentum, olfactory bulb, and medullary nuclei as well as the anterior 
and posterior hypothalamus and pons. In adult mice Ube3a expression is localized in the 
hippocampus, basal ganglia, cerebellum, cerebral cortex, and olfactory bulb. By using 
mice with partial paternal UPD (Uniparental Paternal Disomy), Albrecht et al. (1997) 
were able to differentiate between maternal and paternal expression of Ube3a. The study 
found that in neurons of certain brain regions there was significantly reduced Ube3a 
expression compared to non-UPD littermates, indicating that the maternal allele is the 
primary source of Ube3a expression.  
Research from Yamasaki et al. (2003) determined that in the early stages of 
cellular development and differentiation, neuronal progenitor cells express Ube3a 
biallelically. As differentiation continues and the cell is determined to become a neuron, 
the paternal allele expresses the anti-sense transcript that eventually silences paternal 
Ube3a expression. It is interesting to note that they also found that astrocytes and 
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oligodendrocytes do not silence the paternal allele but express Ube3a from both maternal 
and paternal alleles (Yamasaki et al., 2003). 
 
1.5 Structure of UBE3A 
1.5.1 HECT Domain 
 The linear structure of UBE3A contains several functional domains. The first and 
most well studied domain is the E3 ubiquitin ligase domain, which became the first of a 
new class E3 ubiquitin ligases based on this domain’s C-terminal currently known as the 
HECT (Homologous to E6AP C-Terminus) domain (Huibregtse et al., 1995). The HECT 
domain has a 40-kDa conserved catalytic domain that functions as the binding site of E2 
ubiquitin ligases and can accept ubiquitin from the E2 enzyme, forming an ubiquitin-
thioester intermediate with the conserved HECT domain active site cysteine, Cys820 
(Kumar, Kao, & Howley, 1997, Huang et al., 1999). The HECT domain is then able to 
transfer the ubiquitin to the σ-amino group of the lysine chain on the target substrate by 
catalyzing isopeptide bond formation and creating polyubiquitin chains. 
In the current literature there is no information on the three-dimensional crystal 
structure of UBE3A. However, research by Huang et al. (1999) has elucidated the linear 
structure of the HECT domain to have two distinct lobes, an N-terminal lobe and a C-
terminal lobe connected by flexible hinge segments. The N-terminal lobe, which spans 
residues 495 to 737, is the site of E2 binding, has an elongated shape formed by an α-
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helix structure, and can be subdivided further into large and small N-terminal subdomains 
connected by flexible hinge segments. The C-terminal lobe spans residues 741 to 852, 
has an α/β-structure, and contains the active site cysteine, Cys820. The smaller C-lobe 
packs at one end of the N-lobe, forming an L-shape. This proposed model however, could 
not fully explain how an ubiquitin-thioester intermediate could be formed on UBE3A due 
to geometric restrictions of the position of E2-ubiquitin-thioester upon binding with 
UBE3A. A 41 Å distance between the E2 ubiquitin ligase and Cys820 would normally be 
too far to allow for the nucleophilic attack required for thioester transfer. (Ronchi, Klein, 
& Haas, 2013) 
Further research into the crystal structure of UBE3A by Ronchi, Klein, & Haas 
(2013) elucidated that it contained two E2-ubiquitin binding sites, resolving this issue. 
Using enzyme kinetics, they determined that the first site functions to form the ubiquitin-
thioester intermediate via transthiolation of the ubiquitin molecule from the E2 ligase. 
The location of the first site has not yet been found, but has been proposed to be 
somewhere adjacent to Cys820. The second site has been identified by the study as the 
initial site discovered by Huang et al., (1999) where the uncharged e2 ubiquitin ligase 
binds and is suggested to be the site of polyubiquitin chain elongation. This second site 
contains a 5 - 6 residue long C-terminal extension which contains a conserved 
phenylalanine residue at the fourth or fifth position. Truncation of the carboxy-terminal 
extension or mutation of the phenylalanine results in a loss of polyubiquitination 
function, suggesting that this phenylalanine functions in some way in the catalytic step of 
polyubiquitin chain formation. 
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1.5.2  E6 Binding Domain 
The second domain is an E6 binding domain. It is a leucine rich domain that is 
involved in E6-dependent p53 binding and contains a LxxLL helical leucine motif within 
(Cooper et al., 2003, Zanier et al., 2005). E6 has two Zn2+ binding domains, an N-
terminal domain and a C-terminal domain that are respectively referred to as E6N and 
E6C. A linker helix connects E6N and E6C, creating a hydrophobic pocket on E6 that 
captures the LxxLL motif of UBE3A forming the E6/UBE3A complex required for p53 
ubiquitin targeted degradation (Zanier et al., 2013). 
 
Figure 3. The Linear Structure of UBE3A Appended from Yi et al (2015). The diagram shows known domains of 
UBE3A as well as known mutations. The mutations in black are non-truncating AS-linked mutations and the mutation 
in red is an autism proband mutation identified by Iossifov et al. (2014) Boxed mutations are benign and bold mutations 
were studied by Yi et al. (2015). The SHR domain (not shown) spans amino acids 170 – 680 (Nawaz et al., 1999).  
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1.5.3  Steroid Hormone Receptor Domain 
The next domain is a steroid hormone receptor (SHR) domain, which contains 3 
LxxLL motifs. One motif is located within the C-terminus of UBE3A while the other two 
motifs are located closer to the N-terminus of the protein. These motifs interact with the 
steroid hormone receptors for progesterone, estrogen, androgen, and glucocorticoids. The 
domain is crucial in UBE3A’s other function as a SHR transcriptional activator and the 
LxxLL motifs are common in other steroid receptor coactivators (Nawaz et al., 1999, 
Khan et al., 2006). 
 
1.5.4 AZUL Domain: A Novel Zinc Finger 
As shown in Figure 3, at the N-terminus of UBE3A is a novel Zn-finger domain 
found by Lemak et al. (2011), which they have named AZUL (Amino-terminal Zn-finger 
of UBE3A ligase). The domain contains neither β-turns nor β-strands typical of many Zn-
finger domains and also is not constructed by known Zn-binding motifs. Using NMR, the 
structure of the AZUL domain was determined to be a helix-loop-helix structure where 
the long loop wrapped around a single Zn atom. Within the 23 residue long loop of the 
domain is a series of cysteine residues arranged in a Cys-X4-Cys-X4-Cys-X28-Cys 
configuration. The Zn atom forms a tetrahedral structure coordinated by cysteine 
residues, Cys44, Cys49, Cys54 and Cys83, the C-terminal extension cysteine. This brings 
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the C-terminus and the loop together, maintaining the positions of the two helices. The 
function of the AZUL domain is currently unknown but the study by Lemak et al. (2001) 
reports that it is always accompanying a HECT domain, implying that the AZUL domain 
may have a function closely associated with the function of the HECT domain. It is of 
interest to note that a study by Cooper, Hudson, Amos, Wagstaff, & Howley (2004) 
reports a C44Y mutation that results in a rapid degradation of the C44Y Ube3a mutant in 
vivo compared to the wild-type. 
 
1.6 Dual Function of UBE3A 
UBE3A has two functions. First, through the HECT domain UBE3A acts as an E3 
ubiquitin ligase. Second, using the steroid hormone receptor domain UBE3A acts as a 
transcriptional coactivator for steroid hormone receptors. These two functions are 
independent and discrete. Nawaz et al. (1999) showed that the HECT domain was not 
necessary in order to interact with SHRs and coactivate SHR function. Thus, ubiquitin 
ligase function is not a requirement for transcriptional coactivation function. 
There is some evidence that suggests there may be interplay between the two 
functions of UBE3A. As a component of the ubiquitin-protease-pathway, UBE3A could 
be involved in the regulation of transcription by targeting the transcriptional complexes 
for degradation (Rochette-Egly, 2005). It has also been shown that proteasome inhibition 
significantly diminishes the transcriptional activity of many nuclear receptors and that 
there is a direct correlation between the protein stability of estrogen receptor and 
androgen receptor with the level of Ube3a expression (Nawaz et al., 1999, Gao et al., 
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2005, Ismail & Nawaz, 2005, Khan et al., 2006). However, there currently is no direct 
evidence in the literature suggesting that UBE3A both coactivates and ubiquitinates 
SHRs. 
 
1.6.1 Ubiquitin Ligase Function 
1.6.1.1 Ubiquitin Proteasome Pathway 
The ubiquitin proteasome pathway is one of the major systems in protein 
degradation. The pathway accomplishes this by attaching ubiquitin, a small protein that is 
highly conserved across eukaryotic species, and creating a polyubiquitin chain on the 
target substrate (Ferrier, 2014). A 26S proteasome then deubiquinates and degrades the 
substrate into fragments which are further degraded by cytosolic proteases into amino 
acids to be reused. This is done through a multistep ATP-dependent enzyme cascade 
shown in Figure 4. First, ubiquitin is activated by E1. The activated ubiquitin is then 
transferred to E2. After that the ubiquitin is transferred to the target substrate by E3, 
which is accomplished by various mechanics depending on the class of E3 involved. The 
two major classes are HECT (Homologous to E6AP C-Terminus) and RING (Really 
Interesting New Gene). The former catalyzes the transfer through an active site cysteine 
that accepts the ubiquitin from E2 by forming a thioester bond with ubiquitin. The latter 
acts as a mediator to facilitate the transfer of ubiquitin from the E2-ubiquitin moiety to 
the substrate and does not form an intermediate with ubiquitin (Condon, 2009). UBE3A 
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specifically, first oligomerizes into a homotrimer before catalyzing the formation of the 
ubiquitin-thioester bond (Ronchi et al., 2014). 
The final step before proteasome degradation is the formation and elongation of a 
polyubiquitin chain. The most common form of ubiquitin attachment and polychain 
elongation is K48 polyubiquitination. The first monomer is attached to the substrate by an 
isopeptide link between the α-carboxyl group of the C-terminal glycine of ubiquitin and 
the σ-amino group on the lysine of the substrate. The subsequent ubiquitins are then 
attached to the lysine 48 residue of the previous ubiquitin. When a chain of four K48 
linked ubiquitins are formed on the target substrate is signaled for proteasomal 
degradation. Other common forms of polyubiquitin chain formation include K63-linkage 
and monoubiquitination. K63-links are involved in non-proteolytic functions such as 
cellular signaling and DNA damage repair (Ikeda & Dikic, 2008) while 
monoubiquitination is involved in signaling membrane protein proteolysis via lysosomal 
endocytosis (Haglund, Di Fiore, & Dikic, 2003). According to Kim et al. (2007) UBE3A 
exclusively forms K48 polyubiquitin chains. 
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Figure 4. The Ubiquitin-Proteasome Pathway In an ATP-dependent reaction, ubiquitin is activated by E1. The 
ubiquitin is then transferred to E2. Afterwards, E3 transfers the ubiquitin to the substrate target and may add 
polyubiquitin chains, thus directing the substrate to the next destination. Appended from Condon (2009). 
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1.6.1.2 Regulation of E3 Ubiquitin Ligase Function via PKA Phosphorylation 
 UBE3A is able to target itself for degradation and is thought to be an 
autoregulatory mechanism to maintain appropriate UBE3A levels (de Bie & 
Ciechanover, 2011). Alone, self-degradation may lead to self-elimination if left 
unchecked. Yi et al. (2015) found a novel mechanism for UBE3A regulation that 
circumvents this issue. By studying several missense mutations of UBE3A, they had 
discovered that arginine 482, together with threonine 485, form a canonical PKA 
consensus motif. Using mass spectrometry they determined that T485 was 
phosphorylated by PKA. They studied this motif by transfecting HEK293T cells with a 
UBE3A T485 mutant: either T485A, which cannot be phosphorylated or T485E, which is 
a phosphomemetic version. The study was performed while inhibiting protein synthesis 
in the cells. The findings showed that phosphorylation at T485 inhibited self-
ubiquitination while dephosphorylation increased UBE3A activity. This implies that 
UBE3A’s E3 ubiquitin ligase activity is regulated by inhibition via PKA phosphorylation. 
 
1.7 Steroid Hormone Transcriptional Coactivator 
 Hormone receptors are activated either via ligand binding or through 
phosphorylation (Ferrier, 2014). The receptors then dimerize and translocate to the 
nucleus in order to modify gene transcription. Steroid receptor coactivators are required 
for the activated receptors to influence gene transcription. Without the coactivators, 
hormone receptors cannot modify transcription, and overexpression of steroid receptor 
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coactivators has been found to increase the transcriptional activity of hormone receptors 
by several fold (Condon, 2009).  
 
Figure 5. Mechanism of UBE3A SHR Transcription Coactivation Steroid hormones (in green) bind to SHRs (in 
red) which dimerize, translocate into the nucleus, and bind to HREs (hormone responsive elements) in the promoter 
sequence of the target gene. UBE3A (E6AP) and other coactivators form a p300-CBP (CREB (cAMP response element 
binding protein) Binding Protein/SRC-1 (Steroid Receptor Coactivator-1) complex with the SHR to activate 
transcription via DNA Polymerase II (Pol II) and GTFs (General Transcription Factors). Appended from Chen et al. 
(2015). 
 
UBE3A functions as the coactivator for the steroid hormone receptors of 
progesterone, estrogen, androgen, glucocorticoids, retinoic acid, and thyroid hormone 
(Nawaz et al., 1999). Using chromatin immunoprecipitation (ChIP) assays, UBE3A has 
been found to be recruited in a hormone dependent manner to the promoter region of 
PSA, an androgen receptor responsive gene (Khan et al., 2006). ChIP analysis has also 
determined that UBE3A associates with the p300-CBP (CREB (cAMP response element 
binding protein) Binding Protein/SRC-1 (Steroid Receptor Coactivator-1) complex at the 
estrogen-responsive pS2 promoter as shown in Figure 5. This suggests that UBE3A 
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regulates hormone dependent transcription and is recruited to hormone responsive 
promoters in vivo (Reid et al., 2003, El Hokayem & Nawaz, 2014). 
 
1.8 Substrates of UBE3A 
UBE3A has many substrates it interacts with, in turn influencing many aspects of 
regular cell growth and maintenance. As mentioned previously, UBE3A targets p53, 
which is necessary for cell cycle regulation and has implications in cancer (Ferrier, 
2014). Src-family kinase (SFK) member Blk that has a role in cell survival and migration 
(Frame, 2002) has been demonstrated to be a target as well (Oda, Kumar, & Howley, 
1999). Other targets include CCAAT-enhancer-binding protein alpha (C/EBPα), a critical 
transcription factor involved in granulocytic differentiation and myeloid leukemia (Pal et 
al., 2013) as well as peroxiredoxin-1, an anti-oxidant enzyme involved in the cellular 
response to oxidative stress (Wolyniec et al., 2013). UBE3A can also target components 
of the proteolysis pathway such as Rpn10, the S5a subunit of the 26S proteasome (Uchiki 
et al., 2009, Lee et al., 2014, Tomaić & Banks, 2015). 
Of particular interest to our lab is UBE3A’s involvement with neuronal function. 
UBE3A targets substrates directly involved in neuronal development as well, such as 
ASPM and the SK2 channel that are discussed in further detail below. The protein Arc 
has also been determined to be a target (Greer et al., 2010). However, this finding has 
been challenged by a more recent study that will also be discussed. UBE3A was also 
found to modify pyramidal neurons, which are the primary excitatory neuron cell type 
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found in the cerebral cortex, hippocampus, and amygdala (Miao et al., 2013). While the 
exact mechanism is unknown, the work by Miao et al. suggests that UBE3A modifies 
pyramidal neuron polarity by affecting or working in conjunction with the protein Reelin, 
in order to modulate the localization and function of the Golgi into the dendrite of 
pyramidal neurons. Our laboratory also found in previous experimentation that UBE3A 
regulates the synaptic organizing protein, CBLN1, which has important functions that are 
also discussed in further detail below. 
 
1.8.1 ASPM 
ASPM (abnormal spindle-like microcephaly-associated protein) is a 3477 AA 
long protein that localizes in the centrosome and widely expressed in various tissues 
including the kidney, lungs, muscle, and the brain (Kouprina et al., 2005). It is encoded 
by the ASPM gene where mutations most commonly cause microcephaly, a neurological 
disorder that is characterized by a reduction of brain volume and cranial circumference. 
UBE3A was demonstrated to localize to the centrosome and interact with ASPM 
during mitosis (Singhmar & Kumar, 2011). Their study confirms a molecular cause to the 
diagnostic finding that microcephaly is found in 80% of Angelman Syndrome patients, a 
disease commonly caused by Ube3a (Clayton-Smith & Laan, 2003). The same study also 
observed an increased frequency of apoptosis in Ube3a knockdown cells. Singhmar & 
Kumar (2011) suggest that UBE3A may be required for proper chromosome segregation. 
This means that a loss of function of UBE3A may disrupt mitosis leading to abnormal 
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cytokinesis and apoptosis which may contribute to the mechanism that causes 
microcephaly in AS patients (Singhmar & Kumar, 2011). 
 
1.8.2 SK2 Channel 
The SK2 channel is part of a family of small-conductance calcium-activated 
potassium (SK) channels that modulate synaptic transmission. This is done either by 
promoting repolarization after an excitatory potential or by contributing to the 
afterhyperpolarization following an action potential. By modulating synaptic 
transmissions, SKs participate in regulating neuronal intrinsic excitability (Adelman, 
Maylie, & Sah, 2012) and higher brain functions (Ohtsuki et al., 2012). The SK2 channel 
is located in hippocampal CA1 neurons. The channel opens when the N-methyl-D-
aspartate receptor (NMDAR) is activated and causes a calcium influx. The neuron 
membrane then repolarizes which then turns off NMDAR activity (Ngo-Anh et al., 
2005). This mechanism may control the threshold for induction of long-term potentiation 
(LTP), which is assumed to be involved in learning and memory (Sun et al., 2015). In 
turn, LTP induction regulates synaptic SK2 expression by triggering the endocytosis of 
synaptic SK2 (Lin, Luján, Watanabe, Adelman, & Maylie, 2008). 
 UBE3A was found to facilitate the endocytosis of SK2 by directly ubiquitinating 
the C-terminal domain of the channel and that deficiencies of UBE3A led to increased 
SK2 levels. This inhibits NMDAR function which in turn impairs LTP. Behavioral 
analysis of UBE3A-deficient mice by the same study found that learning and memory 
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were impaired in the context of fear conditioning. This suggests that via SK2 
ubiquitination, UBE3A has a regulatory role in synaptic plasticity and learning. 
 
1.8.3 Arc 
Arc (activity-regulated cytoskeleton-associated protein) regulates the endocytosis 
of AMPA receptors at excitatory synapses. Greer et al. (2010) suggest that the XPC 
domain of Arc is a binding site for Ube3a. Kuhnle et al. (2013) challenge this hypothesis 
by comparing the interaction of other known substrates of UBE3A with XPC domains 
alongside Arc. It was found that UBE3A bound to a different domain, the UBL domain, 
that was present in these two proteins and that Arc had little to no interaction with 
UBE3A. Kuhnle et al. (2013) then found that RNA interference-mediated knockdown of 
Ube3a expression stimulates estradiol-induced Arc transcription. This finding suggests 
that UBE3A regulates Arc transcriptionally as opposed to a posttranslational 
ubiquitination mechanism. Estrogen has been reported to affect Arc transcription 
(Chamniansawat & Chongthammakun, 2009) and as such, UBE3A may regulate Arc 
through Estrogen Receptor transcriptional coactivation. Regardless of the exact 
mechanism by which UBE3A interacts with Arc, the absence of UBE3A leads to an 
increase in Arc levels. In turn, endocytosis of AMPA receptors would increase, resulting 
in fewer AMPA receptors on the plasma membrane at excitatory synapses. This may 
serve to be a possible mechanism for the learning impairments observed in Angelman 
Syndrome patients. 
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1.8.4 Cbln1 
Cerebellin 1 (CBLN1) is a secretory glycoprotein produced in cerebellar granule 
cells that is important in synapse formation and maintenance. It is categorized in a group 
of proteins referred to as synaptic organizers, which help in the formation of functional 
synapses and neuronal circuits. This is accomplished by inducing the differentiation and 
maturation of either pre- or post-synaptic structures depending on where they are 
expressed. These proteins then mediate cell-type specific intercellular interactions which 
determine if the synapse is excitatory or inhibitory. Synaptic organizers include cell 
adhesion molecules such as neurexin (NRX), synaptic cell-adhesion molecule (Syn-
CAM), EphrinB, and leucine-rich repeat transmembrane neuronal proteins (LRRTMs) 
(Biederer et al., 2002, Chih, Engelman, & Scheiffele, 2005, Kayser, McClelland, Hughes, 
& Dalva, 2006, Linhoff et al., 2009). Secreted molecules such as Wnt-7a, fibroblast 
growth factors, thrombospondins, and neuronal pentraxins are also considered synaptic 
organizers ((Eroglu et al., 2009, Hall, Lucas, & Salinas, 2000, Terauchi et al., 2010). 
 CBLN1 is a critical synaptic organizer for parallel fiber (PF)-Purkinje cell 
synapses in vivo (Ito-Ishida, Okabe, & Yuzaki, 2014). A study by Hirai et al. (2005) 
found that mice that lacked Cbln1 expression showed significant reductions of PF-
Purkinje cell synapses resulting in severe ataxia. Further research by Ito-Ishida et al. 
(2008) demonstrated the importance of CBLN1 in PF-Purkinje synapses. Normal PF-
Purkinje cell synapse densities were restored within two weeks of injecting recombinant 
CBLN1 into the subarachnoidal supracerebral space of Cbln1-null mice. When the 
recombinant CBLN1 was degraded, these synapses were lost and ataxia recurred 1 week 
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post injection. Their study shows that CBLN1 is critical in the formation of these 
synapses as well as required for their maintenance. 
CBLN1 accomplishes synapse formation through the formation of a three part 
complex with NRX in the presynapse and GluD2, an ionotropic glutamate receptor in the 
postsynapse (Yuzaki, 2011). Ito-Ishida et al. (2014) conclude that synapse formation in 
Purkinje cells occurs by a 5-step “bidirectional interaction model” as shown in Figure 6. 
1) Purkinje cell spines form independent of input from parallel fibers. 2) PFs and 
Purkinje cell spines make contact, allowing CBLN1 to bind with GluD2. This triggers 
NRX and synaptic vesicles to accumulate at future presynapse sites. 3) CBLN1 interacts 
with NRX that causes the actin cytoskeleton in PFs to rearrange, forming axonal 
protrusions. 4) The contact between Purkinje cell spines and PF protrusions further 
increases NRX-CBLN1-GluD2 interactions, creating a positive-feedback loop. 5) The 
protrusion membrane retracts, leaving a fully formed mature PF-Purkinje synapse. 
 
 
Figure 6. Stepwise formation of PF-Purkinje Synapses Parallel fibers and Purkinje cell spines make contact. CBLN1 
binds to GluD2 receptors on the Purkinje cell, triggering NRX and synaptic vesicles (SVs) to gather at future 
presynaptic sites. PF protrusions increase NRX-CBLN1-GluD2 interactions. This creates a positive feedback loop 
which continues until the protrusion membrane retracts, forming a mature synapse. Appended from Ito-Ishida, Okabe, 
& Yuzaki (2014). 
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 CBLN1 was also found to regulate the formation of molecular layer interneuron 
(MLI)-Purkinje cell synapses. PF-Purkinje synapses, which are excitatory and MLI-
Purkinje synapses, which are inhibitory are important components of cerebellum-
dependent motor learning. In studies analyzing MLI-Purkinje synapses of Cbln1-null 
mice, the density of these synapses is increased compared to wild-type mice. When 
recombinant CBLN1 was introduced the MLI-Purkinje synapse density was restored after 
the recombinant CBLN1 was present for a few days (Ito-Ishida, Okabe, & Yuzaki, 2014). 
Ito-Ishida, Okabe, & Yuzaki, (2014) speculate through their studies that CBLN1-GluD2 
signaling inhibits Src-family tyrosine kinase activity, leading to the inhibition and 
regulation of MLI-Purkinje synapse formation. 
CBLN1 activity was found to be controlled by KCl-depolarization (Iijima, Emi, & 
Yuzaki, 2009). The study found that chronic depolarization of neurons via elevated 
extracellular K+ caused decreases in CBLN1 mRNA expression within several hours in 
mature granule cells. Continued depolarization over the course of several days also 
reduced protein levels of CBLN1 and resulted in a decrease in Purkinje cell dendrites. 
The high K+ medium also prevented the expression of Cbln1 mRNA in immature granule 
cells. This K+ dependent regulation may be a mechanism for PF-Purkinje synapses to 
maintain homeostasis in order to adapt to chronic excitation. 
 Other studies on Cbln1-null mice reveal that CBLN1 influences the dendritic 
structure of striatal neurons as well (Kusnoor et al., 2010). Cbln1 mRNA has also been 
found in neurons of various other brain regions including the mitral layer of the olfactory 
bulb, the entorhinal cortex, and the thalamic parafascicular nucleus (Miura et al., 2006). 
 23 
These findings may suggest that CBLN1 controls synapse formation outside of the 
cerebellum. 
 
1.9 UBE3A Contributes To Disease 
UBE3A is involved in many disease processes due to its dual function; allowing it 
to interact with and regulate various proteins. Examples include various cancers such as 
breast cancer and cervical cancer (Ramamoorthy et al., 2012, Mortensen et al., 2015) as 
well as nervous system pathologies such as Huntington’s Disease (Landles & Bates, 
2004), Parkinson’s Disease (Shimura et al., 2001), and Prader-Willi Syndrome (Jiang et 
al., 1998). Particularly, UBE3A has a significant impact on Angelman Syndrome that is 
caused by mutations that impair the function or expression of Ube3a and Autism 
Spectrum Disorder that is caused by increased dosages of the Ube3a gene. 
 
1.9.1 Angelman Syndrome 
Angelman Syndrome (AS) is a nervous system disease characterized by mental 
development delays with more than 80% of patients displaying microcephaly (Clayton-
Smith & Laan, 2003), severely impaired speech, difficulties learning, dysmorphic facial 
features, and an apparent disposition to happiness with frequent laughter that is unique to 
AS (Williams, 2005). Loss of UBE3A function has been established as the common 
cause of AS pathogenesis. As shown in Figure 7, there are four known genetic 
mechanisms that are responsible for AS (El Hokayem & Nawaz, 2014). First, 
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microdeletions of the maternal 15q11-q13 chromosome, which houses the Ube3a gene, 
are the most frequent cause with more than 70% of AS patients found to have this 
abnormality. Second, mutations in the imprinting center prevent the maternal allele to be 
expressed and are the cause of 8% of AS cases. Third, Uniparental Paternal Disomy 
(UPD), in which the patient inherits two paternal alleles and lacks a maternal allele, 
accounts for 4% of AS cases. Fourth, mutations in the Ube3a gene itself are the cause of 
8% of AS cases. 
 
 
 Figure 7. Genetic Mechanisms of AS Pathogenesis The expression of the maternal allele is critical in the 
formation of AS.  Appended from El Hokayem & Nawaz (2014). 
Studies of AS-linked missense mutations in the Ube3a gene found that several 
mutations clustered near the catalytic cysteine, Cys820, disrupting ubiquitin ligase 
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activity (Sadikovic et al., 2014). Not all AS-linked mutations cluster near the catalytic 
site however and further analysis by Yi et al. (2015) found a loss of UBE3A function can 
be caused by four distinct mechanisms all of which result in an impairments of UBE3A’s 
E3 ubiquitin ligase function as shown in Figure 8. First, many missense mutations are 
found to destabilize the protein independent of ligase activity. Second, some mutations 
promote hyperactive self-degradation resulting in lower levels of UBE3A. Third, several 
mutations cause impairment in activity at the catalytic domain. Fourth, an R482P 
mutation is found to have defective substrate binding. This loss of UBE3A function then 
leads to abnormal neuronal function including synaptic function and plasticity (El 
Hokayem & Nawaz, 2014). 
  
Figure 8. How Missense Mutations Disrupt UBE3A Function AS-linked mutations were tested by Yi et al. (2015) in 
a step wise fashion to determine how the mutations generated AS. They found that the mutants they studied fell into the 
categories displayed in the figure.  Appended from Yi et al. (2015). 
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1.9.2 Autism Spectrum Disorder 
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder defined by a 
range of characterized behaviors. These behaviors are defined by the DSM-5 (Diagnostic 
Statistic Manual-5) as ‘A) Persistent deficits in social communication and social 
interaction across multiple contexts. B) Restricted, repetitive patterns of behavior, 
interests, or activities.’ The severity of ASD is then defined by these conditions: ‘1) 
Symptoms must be present in the early developmental period. 2) Symptoms cause 
clinically significant impairment in social, occupational, or other important areas of 
current functioning. 3) The disturbances are not better explained by intellectual disability 
or global developmental delay.’ (CDC, 2015) 
 According to Geschwind’s review of autism, roughly 200 - 1000 genes have been 
found to be associated with ASD (Chen et al., 2015). Among the vast array of genes, 
Ube3a was found to play a significant role in ASD development. Maternal duplications 
(dup15) and triplications (Idic15) of 15q11-q13, the chromosome that houses the Ube3a 
gene, have been identified in patients with ASD (Cook et al., 1997). Studies have shown 
that in humans, dup15 produces a partially penetrant ASD while Idic15 fully expresses 
ASD (Hogart et al., 2010). Behavioral analysis of mouse models found that a single extra 
copy leads to a partial expression of ASD-like behavior while two copies sufficiently 
impaired social behaviors, similar to human ASD patients (Smith et al., 2011). The mice 
were found to display ASD-like behaviors such as a decreased amount of social 
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interaction, decreased communication and vocalization, as well as repetitive movements 
and grooming (Stoppel, 2014). 
 A whole-exome sequencing study by Iossifov et al. (2014) found an individual 
designated ASD that generated a T485A missense mutation of UBE3A. The site, T485, 
was found by Yi et al. (2015) to be phosphorylated by PKA, turning off UBE3A’s E3 
ubiquitin ligase function. In the T485A mutant, phosphorylation could not occur leading 
to increased targeting for degradation. These studies suggest a perturbation of the 
UBE3A PKA phosphorylation site can lead to neuronal dysfunctions. It remains to be 
determined whether this mutation is responsible for another case of Angelman syndrome 
caused by UBE3A deficiencies or an excessive function of UBE3A as suggested by 
Smith et al. (2011). 
 
1.10 Specific Aims 
 In a previous project, our laboratory discovered that Ube3a copy number affected 
Cbln1 levels. In a study of dose and nuclear dependent down regulation of cortical gene 
expression by Ube3a, our laboratory found that mice with maternal knockout (mKO) of 
Ube3a had increased expression of Cbln1 compared to WT. As shown in Figure 9, when 
the dose of Ube3a was increased 1x and 2x, our laboratory found a dose dependent 
repression of Cbln1 compared to WT.  
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In this current set of experiments our laboratory will determine the functions of 
UBE3Ah needed to regulate Cbln1. We also hypothesize that the phosphorylation state of 
UBE3A affects its subcellular localization between the nucleus and cytoplasm. Thus, we 
propose that the phosphorylation state of UBE3A may influence its ability to regulate 
neuronal genes by controlling its trafficking into and out of the nucleus. 
 
Figure 9 Dose and Nuclear Dependent Down-Regulation of Cortical Cbln1 Gene Expression by Ube3a In a 
previous study, our laboratory found that Ube3a controls Cbln1 gene expression in a dose dependent manner. 
 Mutant forms of UBE3A will be developed to identify how UBE3A interacts with 
CBLN1. The mutants generated are as follows: a ligase dead mutant, a substrate-binding 
mutant, a nonphosporylatable mutant, and a phosphomemetic mutant. A quantitative Real 
Time-PCR (qRT-PCR) will then comparatively measure the expression of Cbln1 in cells 
expressing wild-type Ube3a and the mutants. Based on the results from the qRT-PCR, 
our laboratory can begin to determine a mechanism for regulation of Cbln1 by UBE3A. 
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2 METHODS 
 
2.1 Generating Ube3a Mutants 
  In order to test the mechanism of CBLN1 regulation, four Ube3a mutants were 
formed using human Ube3a isoform III (hUbe3a III). Each of the sites chosen for point 
mutations correspond to the residues from the various UBE3A isoforms and homologues 
found in the literature which are T485E, T485A, E568L, and C820A respectively. The 
hUBE3A III residues that correspond to these mutations were found via the NCBI Gene 
and Protein Reference Sequence Databases. The mutants generated are as follows: 1) 
T505E, a phosphomemetic mutant, 2) T505A, a nonphosphorylatable mutant, 3) E570L, 
a substrate-binding mutant, and 4) C840A, a ligase-dead mutant. 
 
 
The coding sequence of hUbe3a III was amplified from a cDNA clone vector. 
Primers were used to add restriction enzyme sites for SpeI site to the 5’ end and a BamHI 
Table 1. Primer Sequences for hUbe3a III Point Mutations 
Mutant T505A T505E C840A E570L 
Forward 
Primer 
Sequence 
ACGAAGAA
TCgCTGTTC
TCTAC 
ACGAAGAATCgagGTTC
TCTACAGCTTAGTTCA 
ATCTCATACTgcCTT
TAATGTGCTTTTAC 
TGTTTCCAAAct
ATTTTTTCAGCT
GGTTGTGG 
Reverse 
Primer 
Sequence 
TCACTGTACATGCGAATTCTATTGTCA GTAGGTAACCTTTC
TGTG 
CCTCCCTCATCA
ACTCCTTG 
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site to the 3’ end of the amplicon. The recipe for the mix is in Table 2 and was cycled 
using the conditions provided in Table 3. The PCR was run using an Eppendorf 
Mastercycler Nexus Thermal Cycler. The PCR amplicon and pLVX-IRES-mCherry 
vector which was purchased from Clontech (Mountain View, CA) were then digested in a 
hot water bath at 37oC for one hour using SpeI and BamHI following the recipe in Table 
4. The digestions were then run on a gel and extracted. Gel purification was performed 
per the QIA Quick Gel Extraction protocol. 
Table 2.  Recipe for Restriction Site Addition 
ddH2O 32.5 µL 
hUbe3a III Template 1 µL (1 µg) 
dNTPs 1 µL 
10 uM Forward Primer 2.5 µL 
10 uM Reverse Primer 2.5 µL 
5x Buffer 10 µL 
Q5 Polymerase 0.5 µL 
  
 
 
 
 
 
Table 3. PCR Cycle for Restriction Site Addition 
Initial 
Denaturation 
98oC 2 minutes 
Repeat 20x 98oC 10 seconds 
65oC 30 seconds 
72oC 75 seconds 
Final 
Extension 
72oC 2 minutes 
 10oC Hold 
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Figure 10. The Insertion Site of hUbe3a III Into The pLVX-IRES-mCherry Vector hUbe3a III will be inserted 
into the vector using SpeI and BamHI sites present in the vector. 
 
Next, the hUbe3a III amplicon was ligated into the pLVX-IRES-mCherry vector, 
shown in Figure 10. The concentration of insert and vector were determined by a 
nanodrop spectrophotometer. A 3:1 ratio of insert to vector was used and the required 
volumes were calculated using the formula in Figure 11. The mixture was made 
following Table 5. Next, 2.5 µL of ligation was added to 50 µL of E. Coli. The mix was 
placed on ice for 30 minutes followed by heat shock in a 42oC water bath for 30 seconds. 
Table 4. Digestion of hUbe3a III Insert and pLVX-IRES-mCherry Vector 
Insert  Vector  
hUbe3a III PCR 25 µL ddH2O 22 µL 
10x Buffer 3 µL pLVX-IRES-mCherry 2 µL 
SpeI 1 µL 10x Buffer 3 µL 
BamHI-HF 1 µL SpeI 1 µL 
 BamHI-HF 1 µL 
CIP 1 µL 
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The mix was placed back on ice for two minutes. Next, 200 µL of SOC (Super Optimal 
Broth with Catabolite repression) medium was added to the mix and was gently shaken at 
37oC for 15 minutes. Then, 100 µL of the mix was spread onto a selection plate and 
incubated overnight at 37oC. Colonies were picked and grown overnight in 5 mL of LB + 
ampicillin broth at 37oC. The complete pLVX-IRES-mCherry vector with hUbe3a insert 
is shown in Figure 12. 
 
Figure 11. Calculation for Ligation Recipe The volumes of hUbe3a insert and pLVX-IRES-mCherry vector were 
determined using the concentrations of each which were obtained by nanodrop spectrophotometry in ng/µL, the known 
mass of pLVX-IRES-mCherry vector in nanograms (ng), and the known sizes of each in kilo base pairs (kbp). 
 
 
Table 5. Ligation Recipe 
ddH2O 4.7 µL 
hUbe3a Insert 1.90 µL 
pLVX-IRES-mCherry Vector 1.40 µL 
10x Buffer 1 µL 
T4 Ligase 1 µL 
 
DNA was extracted via the QIAprep Spin Miniprep Kit protocol. A PCR was 
performed and gels were run to check for successful transformation and successful 
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ligation with SpeI and BamHI. The Q5 Site-Directed Mutagenesis (SDM) Kit provided 
by New England Biolabs was used to generate the three different point mutations using 
primers listed in Table 1. An amplification mix was created using Table 6 and the mix 
was cycled using the conditions provided in Table 7. The UBE3A mutant constructs were 
then transformed into Stabl3 bacteria via the SDM Kit protocol. The KLD (Kinase, 
Ligase, Dpnl) Reaction of the SDM Kit was performed as shown in Table 8 and the 
plasmids were inserted into Stabl3 bacteria. 
 
Table 6. SDM Amplification Recipe 
 25 µL Final Concentration 
Q5 Hot Start HF 2x Master Mix 12.5 µL 1 X 
10 µM Forward Primer 1.25µL 0.5 µM 
10 µM Reverse Primer 1.25 µL 0.5 µM 
pLVX-Ube3a-IRES-mCherry-
Ascl Plasmid (1 ng/ µL) 
1 µL 1 ng 
ddH2O 9.0 µL  
 
 
Table 7. PCR Cycle for SDM PCR 
 Temp Time 
Initial Denaturation 98oC 30 sec 
Repeat 25 x 98oC 10 sec 
60 oC (T505A), 61 oC (E570L), 
58 oC (C840A, T505E)* 
30 sec 
72 oC 30 sec 
Final Extension 72 oC 2 min 
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Figure 12. The Completed pLVX-Ube3a-IRES-mCherry-Ascl Plasmid The complete plasmid is transfected into 
N2a cells and packaged into Lentivirus. 
 
Table 8. KLD Reaction Recipe 
 Volume Final Concentration 
PCR Product 1 µL  
2X KLD Reaction Buffer 5 µL 1X 
10X KLD Enzyme Mix 1 µL 1X 
ddH2O 3 µL  
 
A midiprep of plasmid DNA was generated using the Nucleobond Xtra Midiprep 
Kit provided by Clontech. The concentration of DNA was determined using nanodrop 
spectrophotometry. The DNA was then sequenced by Dana Farber Harvard Cancer 
Center DNA Resource Core and compared with the wild-type sequence to confirm the 
mutations. Cytoplasmic and nuclear proteins were extracted using the NE-PER Nuclear 
and Cytoplasmic Extraction Protocol by Thermo Scientific from the fourth 6-well cell 
culture plate. 
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2.2 Transfection of N2a Cells 
The PolyJet In-Vitro DNA Transfection Reagent Protocol by SignaGen 
Laboratories (Gaithersburg, MD) was used to transfect the mutant DNA into N2a cells, 
which were chosen for their neuron-like properties. The N2a cells cultured were each 
transfected with a different condition in each well as follows: Wild-Type hUbe3a III, 
IRES-mCherry Vector only, T505A, T505E, E570L and C840A. In each well, 1 mL of 
10% Fetal Bovine Serum (FBS) with antibiotic culture medium was added 30 minutes 
before transfection. Four sets of 6-well plates of N2a cells were prepared using this DNA 
transfection protocol. 
 
2.3 RNA Extraction and cDNA Synthesis of Ube3a Mutants 
The RNA from each condition was isolated from three of the four 6-well cell 
culture plates using TRIzol. Next, cDNA was generated from the RNA isolation via 
reverse transcription. First to remove any genomic DNA, 26 µL of each RNA sample was 
resuspended in 3 µL of 10X DNAse I Reaction Buffer and 1 µL of DNAse I. The 
solution was mixed by vortexing and incubated for 10 minutes at 37oC. Next, 0.5 µL of 
EDTA (Ethylenediaminetetraacetic acid) was added and the solution was heat inactivated 
for 10 minutes at 75oC. Next, 2 µg of each RNA condition was mixed with 2 µL of 
oligo(dT) and 12 µL of ddH2O. The mix was heated at 85
oC for 3 minutes then quickly 
spun and placed on ice briefly. Next the solution mixed with components listed in Table 9 
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and was spun briefly. The solution was incubated for 60 minutes at 44oC. Finally, the 
solution was incubated at 92oC for 10 minutes to inactivate the M-MLV Reverse 
Transcriptase. 
 
Table 9. M-MLV Reverse Transcriptase Reaction Recipe 
 Per Single RNA condition 20X Total 
5X Synthesis Buffer 4 µL 80 µL 
dNTPs 1 µL 20 µL 
RNAse Out 1 µL 20 µL 
M-MLV Reverse Transcriptase 1 µL 20 µL 
 
2.4 Packaging Mutant Ube3a constructs into Viral Vectors 
 The mutant hUbe3a III constructs were packaged into viral vectors based on the 
Addgene pLKO.1 – TRC Cloning Vector protocol. HEK293T cells were prepared for 
transfection in 10 cm dishes with 5 mL of 10% FBS media and incubated at 37oC for 24 
hours. Next, the cells were transfected with lipofectamine-reagent. Seven different 
conditions were prepared, 1) pLVX-hUbe3a III-shRNA, 2) pLVX-IRES-mCherry, 3) 
pLVX-hUbe3a III-IRES-mCherry, 4) pLVX-hUbe3a III T505E, 5) pLVX-hUbe3a III 
T505A, 6) pLVX-hUbe3a III C840A, and 7) pLVX-hUbe3a III E570L. Then, 2.5 µL of 
each condition was mixed with 250 µL DMEM, 0.93 µL psPAX2, and 0.625 µL of VSV-
G. A solution of 250 µL DMEM and 15 µL of PolyJet Reagent was added to each of the 
viral solutions. The mixture was incubated for 20 minutes at room temperature. For each 
of the 7 conditions, a 10 cm dish of HEK293T cells was prepared prior and the mixtures 
were added drop-wise into each dish. The dishes were then incubated at 37oC overnight. 
 37 
 The morning following transfection, the transfection media was removed and 10 
mL of virus collection media composed of sterile, filtered 10% FBS media supplemented 
with 1% Bovine Serum Albumin (BSA) was added to each dish. The dishes were 
incubated at 37oC overnight. The virus media was collected and stored at 4oC. Another 10 
mL of virus collection media was added to each dish and the dishes were incubated at 
37oC overnight. The virus media was collected and was combined with the collection of 
the previous day. The presence of Lentivirus was tested using the Clontech 10 Minute 
Lentiviral Titer Test protocol. Using the Lenti-X GoStix titer provided by the kit, 20 µL 
of virus media was tested. 
 
2.5 Viral Transduction of Primary Cerebellar Neuron Cultures 
Primary cerebellar neurons were harvested from wild-type mice and Ube3a-mKO 
mice per the protocol Isolation and Culture of Post-Natal Mouse Cerebellar Granule 
Neuron Progenitor Cells and Neurons by Lee, H. Y. et al. (2009). The viral transduction 
of the primary cerebellar neuron cultures was performed based on the Addgene pLKO.1 – 
TRC Cloning Vector protocol. The primary cerebellar neuron cultures were split into two 
6-well plates. The virus media that was collected was filtered through a 0.45 µm nylon 
mesh filter and polybrene was added into the media at a ratio of 1:1000. The media from 
the primary cerebellar neuron cultures was removed and replaced with virus-containing 
media. The culture was incubated at 37oC and the infection was allowed to occur over 3 
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days. Afterwards, the cerebellar neuron culture was harvested. RNA was isolated, treated 
with DNAse I, and cDNA was generated using the previously mentioned protocol. 
 
2.6 Measuring mRNA Expression of Cbln1 
A quantitative Real Time-PCR (qRT-PCR) was performed on each of the N2a 
hUbe3a III mutants using the Bio-Rad (Hercules, CA) CFX384 Touch Real Time PCR 
Detection System. Three sets of the following conditions were measured: IRES-mCherry 
control, Wild-Type-hUbe3a, E570L, C870A, T505E, and T505A. Each condition was 
measured with an n of 3 and analyzed in triplicate. The recipes in Tables 10, 11, and 12 
as well as the thermal cycle in Table 13 were used to perform the qRT-PCR. The 
expression of Cbln1 and each hUbe3a III condition was measured. Gapdh was also 
measured because it served as the house keeping gene. The primer sequences used are 
listed in Table 14 and are illustrated in Figure 13. 
 
Table 10. Recipe for hUbe3a qRT-PCR 
 20X Total 
2X Taqman Gene Expression Master Mix 10 µL 200 µL 
cDNA 1 µL - 
hUbe3a PB Primer Mix (10 nmol) 1 µL 20 µL 
hUbe3a FAM/ZEN Probe 1 µL 20 µL 
ddH2O 7 µL 140 µL 
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Table 11. Recipe for Gapdh qRT-PCR 
 20X Total 
2X Taqman Gene Expression Master Mix 10 µL 200 µL 
cDNA 1 µL - 
mouse Gapdh FAM/ZEN/IBFQ Primetime 
Assay  (10 nmol) 
(Assay ID: Mm.PT.39a.1 
Integrated DNA Technologies) 
1 µL 20 µL 
ddH2O 8 µL 160 µL 
 
Table 12. Recipe for Cbln1 qRT-PCR 
 20X 
Total 
2X Taqman Gene Expression Master Mix 10 µL 200 µL 
cDNA 1 µL - 
Cbln1 Primer Mix (20 nmols) 0.5 µL 10 µL 
Cbln1 FAM/ZEN Probe 1 µL 20 µL 
ddH2O 7.5 µL 150 µL 
 
Table 13. Thermocycle for qRT-PCR 
Temperature Time  
95oC 10 minutes  
95oC 15 seconds Repeat 
39x 60oC 1 minute 
 
Table 14. Primer Sequences for qRT-PCR 
Gene Cbln1 hUbe3a III Gapdh 
Forward 
Primer 
GTCTACAACAGA
CAGACCATCCAG 
ATGAACAAGAAAG
GCGCTAGAA 
GGTGAAGGTCGG
TGTGAACG 
Reverse 
Primer 
CCTCGCGTGTCA
CGTCTT 
CCAATAACACGGA
TTAAAGGGGA 
GGTCGTTGATGG
CAACAATCTCC 
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Figure 13 qRT-PCR Diagram of Primers and FAM/ZEN Probe on hUbe3a III and mCbln1 As the primers are 
extended by Taq Polymerase, the FAM probe is degraded by the 5’ to 3’ activity of Taq Polymerase. This allows the 
flourophore to break away from the quencher and fluoresce. The resulting fluorescence is measured and correlates to 
the amount of DNA present in the PCR. 
 
The qRT-PCR data was analyzed using a relative quantification method following 
the qPCR Application Guide (4th ed.) by Brookman-Amissah et al. (2015). An average Cq 
was generated from each condition. Gapdh was used as the housekeeping gene to 
normalize the mean qRT-PCR gene expression data of each condition and obtain a ΔCq 
value using equation 1 of Figure 14. The ΔCq value of each condition was then subtracted 
from the ΔCq of the control condition, pLVX-IRES-mCherry vector, to obtain ΔΔCq 
values as shown in equation 2. The ΔΔCq values for each condition were then averaged 
and the fold change was calculated by using equation 3. 
 
Figure 14 qRT-PCR Equations for Fold Change Appended from qPCR Application Guide 4th ed by Brookman-
Amissah et al. (2015). 
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2.7 Measuring Activity-Dependent Expression of Cbln1 
A primary cerebellar culture was incubated with KCl following the protocol in the 
Iijima, Emi, & Yuzaki (2009) study. The primary cerebellar culture was grown for 18 
days. At the end of the growth period, two plates of cerebellar culture were incubated for 
4 hours, one with 30 mM KCl and one with serum free media only. A qRT-PCR was then 
performed to analyze the expression of Cbln1 in the presence and absence of KCl.  The 
protocols for RNA extraction, cDNA synthesis, and qRT-PCR cycle were done as 
dictated from the previous sections. 
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3 RESULTS 
 
3.1 Site Directed Mutagenesis of hUbe3a III Mutants 
SDM was performed on hUbe3a III to generate the E570L, C840A, T505A, and 
T505E mutants. The resulting constructs were sequenced to validate the mutations. The 
sequence analysis from by Dana Farber Harvard Cancer Center DNA Resource Core is 
shown in Figure 15. When compared to the wild-type hUbe3a III sequence, each mutant 
demonstrates a point mutation in the base pairs altered in the primer sequences from 
Table 1. 
 
Figure 15 Sequences of hUbe3a Mutants E570L, C840A, T505A, and T505E Each mutant variant was compared 
with the wild-type sequence of hUbe3a. The sequence shows point mutations in each mutant when compared to the 
wild-type.  
 
3.2 Quantitative Real Time PCR of N2a Cells 
 To determine how UBE3A regulates Cbln1, four mutants were generated which 
altered the normal function of UBE3A. The mutants are as follows: a phosphomemetic 
mutant, T505E, a nonphosphorylatable mutant, T505A, a substrate-binding mutant, 
E570L, and a ligase-dead mutant, C840A. The mutants of hUbe3a III were generated 
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through SDM and each mutant was transfected into a well of N2a cells. As shown in 
Figure 16, the N2a cells express mCherry suggesting the cells were successfully 
transfected. The RNA from each well of N2a was extracted and cDNA was synthesized 
by reverse transcription. To analyze the expression levels of hUbe3a III and Cbln1 
mRNA within each N2a cell, a qRT-PCR was performed. Each mutant of hUbe3a III was 
measured with an n of 3 and analyzed in triplicate. 
 
Figure 16 Expression of mCherry in N2a Using light microscopy mCherry, a red fluorescent protein, was found to be 
expressed in the N2a cells transfected. Areas that do not show fluorescence suggests some cells were not transfected 
successfully.  
 
As shown in Figure 16 and 17, the hUbe3a III vector was strongly expressed in 
the N2a cell culture. As shown in Figure 18, Cbln1 expression was reduced to about 30% 
of normal when wild-type hUbe3a III or the C840A hUbe3a III mutant were over 
expressed. Additionally there is a 3-fold increase in expression of Cbln1 in the presence 
of the T505A hUbe3a III mutant. There is a slight increase in Cbln1 in the presence of 
the T505E mutant and a slight decrease in Cbln1 in the presence of the E570L mutant. 
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However these changes are not significant as they are within the standard error mean of 
the control. 
 
Figure 17 The Expression of Ube3a Mutants in N2a cells The expression of transfected hUbe3a III is several 
thousand fold greater than the control which is normalized at a value of 1. The largest detected increases in expression 
come from the phosphorylation mutants, T505E and T505A. 
 
 
 
Figure 18 The Expression of Cbln1 in N2a cells Compared to the control, the expression of Cbln1 shows a decrease 
when wild-type hUbe3a III or the C840A hUbe3a mutant are overexpressed. There is an increase in Cbln1 in the 
presence of the T505A hUbe3a III mutant. 
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3.3 Quantitative Real Time PCR of Primary Cerebellar Neurons 
 A primary cerebellar neuron culture was produced by harvesting cerebellar tissue 
from wild-type mice and Ube3a-mKO mice. Lentiviruses containing hUbe3a III mutants 
were produced and each well of Ube3a-mKO cerebellar granular neurons was infected 
with a different mutant. As shown in Figure 19A, the HEK293T cells used in the viral 
packaging protocol were expressing mCherry suggesting the cells were successfully 
transfected. A Lentiviral Titer Test shows that the lentivirus is present, confirming the 
transfection. Figure 19C shows the primary neuronal cells expressing mCherry 
suggesting they were successfully infected. The Ube3a-maternal knockout cells were 
harvested and frozen. Transcriptional analysis of these cells will be done in the future 
following the same methods used with the N2a cells. 
 
Figure 19 Successful Production of Lentivirus A. The HEK293T cell pellet appears violet indicating they express 
mCherry from the pLVX vector. B.  Lenti-X GoStix Lentiviral Titer purchased from Clontech tests positive for the 
presence of lentivirus on the right band. The left band is the positive control. C. The primary cerebellar neuron pellet 
appears violet indicating expression of mCherry from the pLVX vector. This suggests a successful viral transduction. 
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A qRT-PCR of the wild-type primary neuronal cultures was performed using the 
same methods of analysis as the N2a qRT-PCR. The wild-type cerebellar granule neuron 
cultures incubated in the presence of KCl were analyzed in order to measure the 
expression of Cbln1 in response to neuronal activity. The results from the qRT-PCR 
show that compared to the control condition, when the culture was in the presence of KCl 
there was a strong reduction of Cbln1 expression to 1%. This quantitative result replicates 
the findings in the Iijima, Emi, & Yuzaki (2009) study. In the future, our laboratory will 
repeat this experiment with the Ube3a-mKO cultures which will be overexpressing the 
various mutants. This will be done in order to determine if activity-dependent regulation 
of Cbln1 is mediated by UBE3A; particularly via changes in the phosphorylation state of 
UBE3A. 
 
Figure 20 Activity-Dependent Cbln1 Expression In the presence of 30 mM KCl there is a large repression of Cbln1 
expression. 
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4 DISCUSSION 
 
The generation of hUbe3a III mutants was successful as shown by the sequence 
data. The qRT-PCR data shows that the N2a cells were successfully transfected and that 
the hUbe3a III mutants are expressed from the pLVX-IRES-mCherry constructs. The 
N2a cell line is a neuronal progenitor cell line originating from mice. Therefore, no 
hUbe3a should be detected in the pLVX-IRES-mCherry control condition, which is what 
the qRT-PCR data demonstrates. When a hUbe3a III mutant is transfected into the N2a 
cells, the hUbe3a III mutant should be over expressed, which is again demonstrated by 
the significantly large fold increases in the qRT-PCR results. 
As hypothesized by our laboratory, UBE3A contributes to the regulation of 
Cbln1. The qRT-PCR data of this preliminary study shows that wild-type hUbe3a III 
significantly reduces the expression of Cbln1 from 100% to 28%. The expression levels 
of Cbln1 were also reduced in the presence of the C840A ligase-dead mutant to 35% of 
normal expression. Both values are roughly within the standard error mean of each other. 
This may suggest that, because the C840A mutant acts similarly to the wild-type, the 
mechanism of Cbln1 regulation by UBE3A is transcriptional and does not depend on the 
ubiquitin ligase activity of UBE3A. 
Further evidence to support the hypothesis that UBE3A influences CBLN1 levels 
via transcriptional regulation is the change in Cbln1 expression in the presence of the 
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phosphorylation mutants. Cbln1 shows a 3 fold increase in expression when the T505A 
nonphosphorylatable mutant is present. However, when the phosphomemetic mutant 
T505E is present the expression levels of Cbln1 are within the standard error mean for 
the control condition. These results are compatible with experimental results reported by 
Yi et al. (2015) whose data suggests the phosphorylated UBE3A is localized to the 
cytoplasm and excluded from the nucleus. The T505A mutant that acts like a 
permanently nonphosphorylated UBE3A moiety, may localize to the nucleus where it 
somehow interferes with the normal effects of wild-type UBE3A in repressing Cbln1. 
Alternatively, the T505A mutant might simply bind to native Ube3a causing it to be 
degraded. The T505E mutant that acts like a permanently phosphorylated UBE3A 
molecule may be confined to the cytoplasm and therefore is unable to affect transcription. 
If our laboratory’s hypothesis is correct, Cbln1would not be repressed by the T505E 
mutant UBE3A. The results from the qRT-PCR appear to support this, as the expression 
of Cbln1 did not differ from the control condition. 
It is interesting to note that the wild-type and ligase-dead mutant repress Cbln1 
expression while the nonphosphorylatable mutant promotes Cbln1 expression. It is 
possible that the mechanism for localization of UBE3A based on phosphorylation may be 
more complex. It is possible that phosphorylated UBE3A may be in the nucleus as well 
and the phosphorylation state determines how UBE3A regulates Cbln1 transcription. A 
non-phosphorylated state may promote Cbln1 expression, as the qRT-PCR data seems to 
suggest, while a phosphorylated state may repress Cbln1 expression. Our lab extracted 
nuclear and cytoplasmic fractions from N2a cells expressing each mutant. A western blot 
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will need to be performed first on these fractions in order to confirm the localization of 
UBE3A based on its phosphorylation state. 
Another contributing possibility may be that the mouse isoforms of UBE3A 
present in the N2a cell line interact with hUBE3A III. Ronchi et al., (2014) determined 
that the active form of UBE3A forms a homotrimer before catalyzing the formation of the 
ubiquitin-thioester bond. It may be possible that this UBE3A oligomer influences 
transcription as well. Their study did not specify if the different isoforms interact to form 
the homotrimer nor was it determined whether the homotrimer affected the cellular 
localization of UBE3A. Thus, it may be possible in our laboratory’s study that hUBE3A 
is forming homotrimers with mouse isoforms. In the case of the wild-type hUBE3A 
versus the T505A mutant, the homotrimer may also be forming by using moieties in 
different phosphorylation states. It may be that the T505A mutant is interrupting the 
normal wild-type mechanism of Cbln1 regulation. The substrate binding mutant, E570L, 
shows insignificant levels of repression and may be acting through this same mechanism 
as well. Therefore, repression or promotion of Cbln1 expression may be modulated based 
on the combination of UBE3A monomers forming the trimer and might also be 
controlled by the levels of these different trimer combinations present in the nucleus. 
In future studies it will be important to knock out expression of endogenous 
mouse UBE3A. It is also important to note that N2a cells express Cbln1 at significantly 
lower levels than fully formed adult neuronal cells. The next study to be done in this 
series is to test the expression of Cbln1 in the primary cerebellar culture that was 
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generated from Ube3a maternal knockout mice. Performing the study on cerebellar 
granular neurons from Ube3a-mKO mice would allow only exogenous Ube3a to be 
expressed, thus removing the possible interference from the endogenous wild-type mouse 
Ube3a. Additionally, cerebellar neurons express Cbln1 at much higher levels than N2a 
cells, allowing for a more accurate measurement during qRT-PCR. Our laboratory will 
also be able to further study whether UBE3A is involved in activity-dependent regulation 
of Cbln1 using this cell line. 
It is important to continue these types of studies because CBLN1 may be 
implicated in the pathogenesis of AS and ASD phenotypes. CBLN1 plays a significant 
role in synapse formation of Purkinje cells (Ito-Ishida, Okabe, & Yuzaki, 2014). Due to 
Ube3a’s involvement in AS and ASD, mutations involved in the pathogenesis of both 
diseases may be acting through aberrant regulation of Cbln1 which would thereby affect 
synapse formation. Hirai et al. (2005) found that mice lacking Cbln1 expression showed 
severe ataxia due to significant reductions of PF-Purkinje cell synapses. Thus, it may be 
possible that regulation of Cbln1 by UBE3A may contribute to the motor dysfunction 
present in both pathologies such as speech impairment and repetitive behavior. Future 
therapies for both diseases would then include gene therapy to correct mutations in 
Ube3a or to deliver exogenous Ube3a with the proper phosphorylation state. 
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